Could a single injection replace biopsies for breast cancer?
NCT ID NCT07292571
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial is testing a new imaging agent called [99mTc]Tc-ZHER2:4107 to see how well it can detect different levels of HER2 protein in breast cancer tumors. Fifty participants will receive one injection followed by a SPECT/CT scan. The goal is to improve diagnosis and help doctors choose the right treatment without needing a tissue biopsy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Technetium-99m-labelled affibody [99mTc]Tc-ZHER2:4107
What this could lead to
If successful, this imaging method could help doctors better identify HER2 status in breast cancer without needing a biopsy, guiding more personalized treatment.
What could go wrong
This is a small early-phase trial with only 50 participants, so results may not apply to all patients. The imaging agent's accuracy and safety are still being tested.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Research Institute of Tomsk National Research Medical Center of the Russian Academy of Sciences
Tomsk, Russia